ArticleTransplantation direct2022
Induction in Pancreas Transplantation: T-cell Depletion Versus IL-2 Receptor Blockade.
Article in Transplantation direct, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Simultaneous Pancreas and Kidney Transplant Recipients From Pediatric Donors Have Comparable Outcomes to Those From Adult Donors, Regardless of the Type of Donation.Transplantation direct · 2026Article
- Pretransplant Malnutrition Risk Components are Associated With Adverse Outcomes After Simultaneous Pancreas and Kidney and Solitary Pancreas Transplantation.Clinical transplantation · 2026Article
- Locus-specific HLA matching and induction therapy in simultaneous pancreas-kidney transplantation: a national UK cohort study.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study.Scientific reports · 2025Article
- Predicted Indirectly Recognizable T-cell Epitope (PIRCHE) Load Correlates With Rejection Events After Simultaneous Pancreas-Kidney Transplantation.Transplantation direct · 2025Article
- Importing pancreata for transplantation: a single-center experience across evolving allocation eras.Frontiers in transplantation · 2025Article
- Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Risk Factors for Early Post-transplant Weight Changes Among Simultaneous Pancreas-kidney Recipients and Impact on Outcomes.Transplantation direct · 2024Article
- Simultaneous Pancreas-Kidney Transplant Outcomes Stratified by Autoantibodies Status and Pretransplant Fasting C-peptide.Transplantation direct · 2024Article
- Analysis of Individual Components of Frailty in Simultaneous Pancreas and Kidney, and Solitary Pancreas Transplant Recipients.Transplantation direct · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is limited data exist on relative outcomes with T-depletion versus IL-2 receptor (IL2R) blockade induction in pancreas transplantation. Methods: We analyzed all patients who underwent simultaneous pancreas-kidney or pancreas transplant alone at our institution between January 1, 2011, and December 31, 2019. Results: Of 417 pancreas transplant recipients, 291 received induction with a T-depleting agent and 126 received induction with an IL2R blocker. No difference was detected in pancreas allograft death-censored ( Conclusion: Our data suggest that IL-2 receptor blockade may be a reasonable choice of induction for pancreas transplant recipients at low immunologic risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.